Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker (Nasdaq: BRKR) has acquired the DISQVER® clinical metagenomics platform from Noscendo, expanding its NGS-based infection detection portfolio. DISQVER provides advanced bioinformatics and reporting for rapid, comprehensive whole genome sequencing (WGS) analysis directly from cell-free human blood samples without prior cultivation.
According to Bruker, the DISQVER platform can search WGS data for more than 11,000 different microbes and parasites, delivering metagenomic next-generation sequencing (mNGS) results from blood-derived cell-free DNA in less than 24 hours after sample receipt. The approach targets research applications in bloodstream infections, sepsis, endocarditis and other severe infectious diseases. Following the acquisition, DISQVER will remain for research use only while Bruker pursues diagnostic registration. Financial terms were not disclosed, and DISQVER is not expected to be material to Bruker’s FY26 financial results.
Bruker (Nasdaq: BRKR) is highlighting its expanding Microbiology & Infection Diagnostics portfolio at ASM Microbe 2026, including MALDI Biotyper, IR Biotyper and MBioSEQ workflows. Enhancements feature an FDA‑cleared library of 549 microbial species, RUO/GP libraries covering 5,325 species, and tools for faster sepsis and bloodstream infection diagnostics.
According to Bruker, robust U.S. demand for MALDI Biotyper and IR Biotyper drove 140 new system placements in 2025, with double‑digit consumables growth and continued double‑digit U.S. microbiology growth into 2026.
Bruker (Nasdaq: BRKR) launched the new timsMRMS mass spectrometry platform for ultra-complex mixture analysis in the energy sector.
The system combines TIMS and extreme-resolution MRMS, offering >10M mass resolution, sub-ppm accuracy and isotope fine structure to support petroleomics, sustainable fuels and advanced energy storage research.
Bruker (Nasdaq: BRKR) announced major advances in 4D proteomics, metabolomics and air exposomics at ASMS. New launches include the timsMRMS ultra-high-resolution mass spectrometer, enhanced timsUltra AIP bottom-up proteomics workflows, and timsOmni top-down proteoform characterization with ~4x higher sensitivity.
Bruker also introduced AI-enabled OmniScape, ProteoScape and GlycoScape 2027 software, an early-access hybrid qualitative/quantitative 4D metabolomics workflow, and new TOFWERK airborne molecular contaminant TOF-MS tools, supported by a multi-million-dollar order from a leading global memory manufacturer.
Bruker (BRKR) has commissioned a BioSpec 18 Tesla preclinical MRI, described as the world’s highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal.
The 18T system enhances spatial resolution and sensitivity for advanced MRI and MRSI in oncology and neuroscience, supporting in vivo studies of cancer, metastasis, brain plasticity and neural activity, and the discovery of translational imaging biomarkers.
Bruker (Nasdaq: BRKR) reported Q1 2026 revenue of $823.4M, up 2.7% year-over-year and down 4.4% organically. Q1 GAAP diluted EPS was $0.02 and non-GAAP diluted EPS was $0.31. BSI bookings grew high-single-digits organically and book-to-bill stayed above 1.0x.
The company reconfirmed FY2026 guidance: revenue of $3.57–$3.60B (+4%–5% reported; +1%–2% organic) and non-GAAP EPS of $2.10–$2.15 (includes ~8% FX headwind).
Bruker (Nasdaq: BRKR) will report Q1 2026 financial results before market open on Wednesday, May 6, 2026, with a conference call and webcast at 8:00 a.m. ET.
A slide presentation will be posted shortly before the webcast. Investors may join via the investor website, phone (U.S. or international), or pre-register for a personalized dial‑in and PIN. A telephone replay is available through June 6, 2026.
Bruker (Nasdaq: BRKR) will showcase new cross-platform spatial biology workflows and high‑plex datasets at AACR 2026, including GeoMx-to-CellScape, CellScape-to-CosMx, a 208-plex CellScape XR spatial proteomics dataset, the PaintScape 419-plex panel, and commercial shipments expected this quarter or summer.
These updates emphasize integrated multiomic workflows linking whole transcriptome, proteomics, and 3D genome imaging for translational oncology research.
Bruker (Nasdaq: BRKR) launched the MyGenius PRO high-throughput, fully automated sample-to-answer PCR molecular diagnostics system in Europe on April 17, 2026.
At launch the IVDR-compliant menu includes CMV, EBV (whole blood) and BKV (urine), with additional IVDR assays planned throughout 2026. The platform was co-developed with ELITechGroup and Hitachi High-Tech (Japan: LABOSPECT GA-5).
Bruker (NASDAQ:BRKR) announced portfolio enhancements at ESCMID Global 2026 across MALDI Biotyper, IR Biotyper, MBioSEQ Ridom Typer and integration of Molzym.
Key items: MBT Easy T kit (supports up to 2,000 samples), reference libraries expanded to 5,300+ species (+600 species), IVDR and US clinical studies targeting FDA submissions in 2026, and new IR Tracker outbreak surveillance capabilities.